Clinical trials: Eisenmenger Complex
Congenital Heart Disease (CHD), Eisenmenger Syndrome
Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome
The present study seeks to provide pilot data on the safety and efficacy of medical therapy with sotatercept in patients with an established diagnosis of congenital heart disease and Eisenmenger syndrome.
- Conditions
- Congenital Heart Disease (CHD), Eisenmenger Syndrome, PAH
- Trial name
- CHASE (NCT07498803)
- Testing
- Sotatercept
- Volunteers
- 40 people
- Sponsor
- Philipps University Marburg
Pulmonary Arterial Hypertension
Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease
The prevalence of PAH associated with congenital systemic-to-pulmonary shunts in Western countries has been estimated to range between 1.6 and 12.5 cases per million adults, with 25-50% of this population affected by…
- Trial name
- EIGER (NCT01383083)
- Volunteers
- 42 people
- Sponsor
- Maryknoll Medical Center
Eisenmenger Syndrome, Congenital Heart Disease
Sleep-disordered Breathing in Eisenmenger Syndrome
Sleep-disordered breathing (SDB) is a wellknown comorbidity in cardiovascular disease. Knowledge about SDB in adult congenital heart disease is limited.
- Conditions
- Eisenmenger Syndrome, Congenital Heart Disease, Sleep-disordered Breathing
- Trial name
- NCT02614417
- Testing
- Polysomnography
- Volunteers
- 20 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular…
- Trial name
- SuMILE (NCT07356778)
- Testing
- Sotatercept, vasodilator-based PAH therapy
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Kazuya Hosokawa
Eisenmenger Syndrome
Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome
A preliminary observational study by the investigators has shown that tadalafil, a selective phosphodiesterase-5 inhibitor (PDE-5) decreases pulmonary vascular resistance(PVR) in patients of eisenmenger syndrome (ES) resulting in…
- Trial name
- NCT01200732
- Where
- India
- Volunteers
- 28 people
- Sponsor
- Govind Ballabh Pant Hospital
Eisenmenger Syndrome
Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome
The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial hypertension associated with congenital heart disease.
- Trial name
- NCT05611268
- Testing
- Pentoxifylline
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- University of Sao Paulo General Hospital